Defination Uses Various processes in Tissue - culture
…
continue reading
Welcome to the Biotech Bytes podcast, where we sit down with Biotech and Pharma IT leaders to learn what's working in our industry. Steven Swan is the CEO of The Swan Group LLC. He has 20 years of experience working with companies and individuals to make long-term matches. Focusing on Information technology within the Biotech and Pharmaceutical industries has allowed The Swan Group to become a valued partner to many companies. Staying in constant contact with the marketplace and its trends a ...
…
continue reading
Biotechnology for Tomorrow
…
continue reading
DrugPatentWatch serves leading companies ranging from biopharmaceutical R&D to healthcare delivery, and has been cited by CNN, NEJM, Nature Journals, and many other leading publications. Use cases for the DrugPatentWatch platform include: - Branded pharmaceutical global business intelligence and forecasting - Generic drug and API manufacturer portfolio management - Wholesalers preventing overstock of off-patent drugs - Healthcare payer formulary management and budget management
…
continue reading
What happens when robots, AI, and big data enter the hospital? Glenn Cohen (a professor and deputy dean at Harvard Law School) is unpacking that question in this exploration of biotechnology, ethics, medical law, and health care policy. Each week, he’ll interrogate a single technology – such as digital pills, AI-powered decision support algorithms, or digital health apps – through the lens of ethical concerns like informed consent, liability, and privacy.
…
continue reading
1
Garbage In, Garbage Out: Science, Data, Technology with Jonathon Hill
31:02
31:02
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
31:02
Science isn't just about discovery; it's about doing it right to ensure reliability and validity. Joining me is Jonathon Hill, an epitome of a scientist, educator, innovator, and the Co-founder and Vice President of Science and Technology at Wasatch Biolabs. Although trained initially as a premed, Jonathon's professional journey took a deep dive in…
…
continue reading
1
Data is the key to AI with Keshia Maughn
31:20
31:20
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
31:20
The intersection of data and artificial intelligence forms the cornerstone of today's healthcare innovation, transforming the way we approach medical advancements. In this week’s episode, I'm excited to welcome Keshia Maughn from STATinMED, a company carving out its space with a focus on specialized data solutions in biotech. We look at the nuances…
…
continue reading
1
Digital Enterprise Capabilities: Beyond IT with Matt Lasmanis
35:17
35:17
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
35:17
How do today’s biotech companies cultivate innovation and harness digital tools for strategic growth? In this episode, we dissect the pivotal role that digital enterprise capabilities play in transforming a company's approach to challenges in the life sciences sector. As I chat with Matt Lasmanis, Chief Technology & Innovation Officer at Sage Thera…
…
continue reading
Drug repurposing, or identifying new therapeutic uses for existing drugs, is gaining significant momentum as a promising approach to accelerate drug development and reduce costs. This book chapter provides a…SourcePar DrugPatentWatch
…
continue reading
The pharmaceutical industry in China is undergoing a significant transformation with the adoption of artificial intelligence (AI) technology. A recent study published in the Future Journal of Pharmaceutical Sciences evaluates…SourcePar DrugPatentWatch
…
continue reading
A paper presented at the 2nd International Conference on Systems Medicine, AI, and Drug Repurposing proposes a novel approach to overcoming the financial barriers associated with repurposing generic drugs through…SourcePar DrugPatentWatch
…
continue reading
1
Diverse AI with Rajvir Madan
35:03
35:03
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
35:03
The diverse applications of artificial intelligence are transforming industries at an unprecedented pace, but with great breakthroughs come complex challenges. Today I'm joined by Rajvir Madan, Chief Digital and Technology Officer at Arcutis Biotherapeutics, to break down the transformative impact AI is having in our field. Our discussion spans fro…
…
continue reading
A recent study published in JAMA Health Forum sheds light on the impact of biosimilar competition on patient out-of-pocket (OOP) costs for biologic drugs in the United States. The research,…SourcePar DrugPatentWatch
…
continue reading
1
Patients Benefiting from Technology with Christopher J Kouzios
31:32
31:32
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
31:32
The intersection of healthcare and technology paves the way for revolutionary patient care, shaping the future with precision and personalization. Today, the spotlights are on how getting data ready for AI applications is changing the game in healthcare. I'm thrilled to welcome Christopher J Kouzios, the Principal Owner of Kooz Technologies, an exp…
…
continue reading
A recent article in Communications of the ACM explores opportunities for “Permissionless innovation” in pharmaceuticals. “Permissionless innovation” refers to the freedom to explore new technologies or businesses without needing prior…SourcePar DrugPatentWatch
…
continue reading
1
HR Policies for AI with Bill Pierce
59:12
59:12
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
59:12
How do we navigate the complexities of workforce management in the era of artificial intelligence? Today's discussion sheds light on the intricacies of HR policies as they adapt to the technological advancements in AI. I’m joined by Bill Pierce, Chief Information Officer at BioIVT, a visionary in leveraging technology to enhance business processes.…
…
continue reading
LACTOSE-Free Medicines, 2024 is part of DrugPatentWatch’s deep library of business intelligence on biopharmaceutical drugs. Buy Lactose-Free Medicines from Amazon This guide is designed to provide information for healthcare providers to…SourcePar DrugPatentWatch
…
continue reading
GELATIN-Free Medicines, 2024 is part of DrugPatentWatch’s deep library of business intelligence on biopharmaceutical drugs. Buy Gelatin-Free Medicines on Amazon This guide is designed to provide information for healthcare providers to…SourcePar DrugPatentWatch
…
continue reading
1
Getting Data Ready for AI Applications with Elisabeth Schwartz
23:35
23:35
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
23:35
The impact of AI on data management, particularly in the realm of biotechnology, is undeniable. It has fundamentally transformed how we approach and utilize vast amounts of data in this field. Joining me is Elisabeth Schwartz, the IT Head at Phathom, to explore the crucial task of preparing data for AI applications and the hurdles we face in ensuri…
…
continue reading
Switching pharmaceutical excipients, the inactive components used in drug formulations, can have significant implications for both production costs and market appeal. These components, while not contributing directly to the therapeutic…SourcePar DrugPatentWatch
…
continue reading
Elevate your excipient business strategies with the comprehensive Drug Excipient Business Development Reports from DrugPatentWatch. Designed for excipient manufacturers seeking lucrative opportunities in the pharmaceutical industry, these reports offer invaluable…SourcePar DrugPatentWatch
…
continue reading
1
IT helping to drive business P&L with Eduard De Vries
43:11
43:11
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
43:11
The convergence of technology and business savvy is reshaping the biotech landscape. Today's leaders are adept at harnessing IT to drive profitability and impact lives, turning data and innovation into strategic gold. In this episode, I sit down with Eduard De Vries, a visionary at the intersection of IT and healthcare business strategy. Eduard sha…
…
continue reading
1
Data Protection in AI Adoption with Bob McCowan
36:18
36:18
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
36:18
A revolution in biotechnology is underway, with artificial intelligence at its core, but the fervor over AI adoption brings with it pressing concerns about data protection that cannot be overlooked. In this episode, I'm joined by Bob McCowan, Chief Information Officer at Regeneron, to navigate the crossroads of AI development and data security. We …
…
continue reading
The recent paper published in PLOS ONE presents a novel approach for efficiently retrieving a substantial number of patents related to specific technologies. The authors enhance an automated patent landscaping…SourcePar DrugPatentWatch
…
continue reading
A recent article published in Health Affairs, delves into the Federal Trade Commission’s (FTC) concerns regarding the inclusion of improper patents in the FDA’s Orange Book by pharmaceutical manufacturers. The…SourcePar DrugPatentWatch
…
continue reading
1
Exploring AI Integration in Biotech with David Williamson
31:50
31:50
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
31:50
Automation has become a pivotal force in the advancement of the biotech sector, ushering in a new era of AI-driven solutions. In this episode, I'm joined by David Williamson, the CIO at Abzena and a trailblazer in biotech innovation. We're peeling back the layers of AI integration, from commercial chatbots that defy the conventional, to AI's grip o…
…
continue reading
1
Fireside Chat: I. Glenn Cohen and Rochelle Walensky
38:31
38:31
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
38:31
Professor Glenn Cohen, Faculty Director of the Petrie-Flom Center at Harvard Law School interviews Dr. Rochelle Walensky, 19th Director of the Centers for Disease Control and Prevention and Senior Academic Fellow at the Petrie-Flom Center. They discuss Dr. Walensky’s career as an infectious disease clinician focused on HIV/AIDS, her experience lead…
…
continue reading
A recent article published in the Journal of Cheminformatics addresses the challenge of confirming the patent status of newly developed compounds, particularly in the pharmaceutical industry, where generating novel structures…SourcePar DrugPatentWatch
…
continue reading
A recent story by NPR echoes the findings of a collaboration between DrugPatentWatch and Bloomberg, which examined increasing competition between generic drug makers. The NPR article discusses the challenges in…SourcePar DrugPatentWatch
…
continue reading
The article “Settled: Patent characteristics and litigation outcomes in the pharmaceutical industry,” explores the relationship between Paragraph IV litigation characteristics and the probability of a Paragraph IV settlement in the…SourcePar DrugPatentWatch
…
continue reading
1
The Rise of AI in Pharma & Biotech with Bill Wallace
35:56
35:56
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
35:56
Welcome to the first episode of the Biotech Bytes podcast! Today, we have an insightful conversation with Bill Wallace from Intercept Pharmaceuticals, exploring the transformative role of AI in the pharmaceutical and biotech industries. Bill talks about how working together and keeping data safe are key in these industries. He dives into the specif…
…
continue reading
Welcome to the Biotech Bytes podcast, where we sit down with Biotech and Pharma IT leaders to learn what's working in our industry. Steven Swan is the CEO of The Swan Group LLC. He has 20 years of experience working with companies and individuals to make long-term matches. Focusing on Information technology within the Biotech and Pharmaceutical ind…
…
continue reading
In the ever-evolving landscape of the biotech and pharmaceutical sectors, accurate valuation of post-revenue drug assets stands as the linchpin for informed and strategic decision-making. The significance of this valuation…SourcePar DrugPatentWatch
…
continue reading
Researchers from West Virginia University College of Law have conducted a study examining the frequency of drug patent invalidations based on inequitable conduct. The findings, published in JAMA, shed light…SourcePar DrugPatentWatch
…
continue reading
In a recent article in Pharmaceutical Executive, Alan Kalton, Senior Vice President of Commercial Strategy at Aktana, sheds light on the critical challenges facing pharmaceutical companies as they confront impending…SourcePar DrugPatentWatch
…
continue reading
1
Maximizing Intellectual Property Value in the Biomedical Sector: A Case Study on Rucaparib Patents
A paper titled “Analysis of Strategy for Extending Patent Protection of Rucaparib” by Zhifeng Wang. discusses the strategies employed by pharmaceutical companies to extend the patent protection period of the…SourcePar DrugPatentWatch
…
continue reading
1
Advancements in In Silico ADMET Modeling: A 20-Year Journey of Machine Learning in Drug Discovery at Bayer Pharma
Over the past two decades, Bayer Pharma has developed an in silico absorption, distribution, metabolism, and excretion (ADMET) platform with the aim of generating models for various pharmacokinetic and physicochemical…SourcePar DrugPatentWatch
…
continue reading
DrugPatentWatch has published a list of research papers citing DrugPatentWatch at https://www.drugpatentwatch.com/citations/ DrugPatentWatch.com is your key to unlocking the world of pharmaceutical research. These primary literature citations can benefit researchers,…SourcePar DrugPatentWatch
…
continue reading
Should Social Robots be Used to Provide Emotional Support? PARO is a cuddly baby seal used as an emotional companion robot in elder care. Emotional companion robots provide some of the benefits of therapy animals, without the attendant challenges of a live animal. But while emotional companion robots can provide comfort to older adults, they might …
…
continue reading
How Should We Regulate Digital Health Technology? The current digital health marketplace has been described as a wild west. Every day, consumer products making strong claims are brought to market without sufficient evidence and often withdrawn only when enforcement actions are brought against them. There are already apps that claim to detect melano…
…
continue reading
In a systematic review titled “Influencers of Generic Drug Utilization,” researchers aimed to shed light on the key factors influencing the use of generic prescription drugs in the United States.…SourcePar DrugPatentWatch
…
continue reading
How AI Bias Is Affecting Health Care—And What We Can Do About It People are biased, and people build AI, so AI are biased, too. When AI is used in hospitals to treat patients, that bias comes to health care. For example, a 2019 paper in Science found that a commercial risk-prediction tool was less likely to refer equally sick Black people than whit…
…
continue reading
The article titled “Reviving an R&D Pipeline: A Step Change in the Phase II Success Rate” discusses Pfizer’s efforts to improve its research and development (R&D) productivity. The pharmaceutical industry…SourcePar DrugPatentWatch
…
continue reading
1
Privacy from the Inside Out
21:44
21:44
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
21:44
How secure is data collected by digital pills? Ingestible electronic sensors (IESs or “digital pills”) can be taken with or as a part of a drug in order to collect and record patient data, such as medication adherence or physiological metrics. This information can then be shared with relevant parties, including the patient, family members, and heal…
…
continue reading
The FDA conducted a study to identify factors that may predict the likelihood of generic drug marketing applications. The study focused on abbreviated new drug applications (ANDAs) submitted to the…SourcePar DrugPatentWatch
…
continue reading
Who Is Liable When AI Injures a Patient? Medical errors happen; doctors are only human. And when doctors make mistakes, the law pertaining to who is liable is usually clear-cut. But what happens if the mistake was made by an AI, included one embedded in a device or a robot? This episode will explore who is liable. Is it the hospital? The developer …
…
continue reading
“Measuring Patent Value Indicators with Patent Renewal Information” aims to address the research gap by constructing a dynamic model that incorporates both ex ante and ex post patent value indicators.…SourcePar DrugPatentWatch
…
continue reading
Do You Own Your Personal Health Data? Every time you visit the doctor, heaps of personal health data are stored in electronic medical records, a mainstay of the modern health care industry. The rise of big data in healthcare comes with risks, however. Health data is now being sold to external companies and researchers. So, can you own your personal…
…
continue reading
The article “Maximizing the Value of Drug Patents Before Losing Exclusivity” discusses strategies for biomedical companies to maximize the value of their drug patents before the exclusivity period expires. In…SourcePar DrugPatentWatch
…
continue reading
In a recent STAT article Sanofi CEO Paul Hudson discusses the potential of artificial intelligence (AI) in the pharmaceutical industry. While some in the industry have been hesitant to embrace…SourcePar DrugPatentWatch
…
continue reading
In the world of patents, the right to exclude others from using or selling an invention is granted only during the patent’s validity. Once a patent expires, this exclusivity vanishes.…SourcePar DrugPatentWatch
…
continue reading
Should We Tell Patients When AI is Being Used in Their Care? Increasingly, AI is being used in hospitals without patients’ knowledge of its use in their care, let alone their consent. For example, AI is being used to predict the likelihood that a cancer patient will die within the next six months. Hospitals and clinicians are deploying this technol…
…
continue reading
Pharmacists play a crucial role in drug repurposing due to the vast amount of opportunities that exist in this innovative approach. Drug development and registration can be costly, time-consuming, and…SourcePar DrugPatentWatch
…
continue reading
In a guest column Kevin Wall, principal consultant and owner of Cincero Consulting, emphasizes the critical importance of selecting the right Contract Development and Manufacturing Organization (CDMO) for drug product…SourcePar DrugPatentWatch
…
continue reading
Loss of exclusivity (LOE) doesn’t have to spell doom for branded drug revenue streams. In the face of impending patent expirations, pharmaceutical companies can adopt key approaches to preserve meaningful…SourcePar DrugPatentWatch
…
continue reading